98 related articles for article (PubMed ID: 34887127)
1. Mutations in muscle-type creatine kinase impact HIV prevention.
Migliorati JM; Zhong XB
Trends Pharmacol Sci; 2022 Mar; 43(3):165-167. PubMed ID: 34887127
[TBL] [Abstract][Full Text] [Related]
2. Naturally Occurring Mutations to Muscle-Type Creatine Kinase Impact Its Canonical and Pharmacological Activities in a Substrate-Dependent Manner In Vitro.
Mosher EP; Eberhard CD; Bumpus NN
Mol Pharmacol; 2021 Dec; 100(6):588-596. PubMed ID: 34561299
[TBL] [Abstract][Full Text] [Related]
3. Discovery of Genetic Variants of the Kinases That Activate Tenofovir in a Compartment-specific Manner.
Lade JM; To EE; Hendrix CW; Bumpus NN
EBioMedicine; 2015 Sep; 2(9):1145-52. PubMed ID: 26501112
[TBL] [Abstract][Full Text] [Related]
4. The Vaginal Microbiome and its Potential to Impact Efficacy of HIV Pre-exposure Prophylaxis for Women.
Velloza J; Heffron R
Curr HIV/AIDS Rep; 2017 Oct; 14(5):153-160. PubMed ID: 28812207
[TBL] [Abstract][Full Text] [Related]
5. Perspectives on the utility and interest in a point-of-care urine tenofovir test for adherence to HIV pre-exposure prophylaxis and antiretroviral therapy: an exploratory qualitative assessment among U.S. clients and providers.
Bardon AR; Simoni JM; Layman LM; Stekler JD; Drain PK
AIDS Res Ther; 2020 Aug; 17(1):50. PubMed ID: 32762713
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of a Multidrug Assay for Monitoring Adherence to a Regimen for HIV Preexposure Prophylaxis in a Clinical Study, HIV Prevention Trials Network 073.
Zhang Y; Clarke W; Marzinke MA; Piwowar-Manning E; Beauchamp G; Breaud A; Hendrix CW; Cloherty GA; Emel L; Rose S; Hightow-Weidman L; Siegel M; Shoptaw S; Fields SD; Wheeler D; Eshleman SH
Antimicrob Agents Chemother; 2017 Jul; 61(7):. PubMed ID: 28438932
[TBL] [Abstract][Full Text] [Related]
7. Discovery of genetic variants of the kinases that activate tenofovir among individuals in the United States, Thailand, and South Africa: HPTN067.
Figueroa DB; Tillotson J; Li M; Piwowar-Manning E; Hendrix CW; Holtz TH; Bokoch K; Bekker LG; van Griensven F; Mannheimer S; Hughes JP; Grant RM; Bumpus NN
PLoS One; 2018; 13(4):e0195764. PubMed ID: 29641561
[TBL] [Abstract][Full Text] [Related]
8. Acquisition of wild-type HIV-1 infection in a patient on pre-exposure prophylaxis with high intracellular concentrations of tenofovir diphosphate: a case report.
Hoornenborg E; Prins M; Achterbergh RCA; Woittiez LR; Cornelissen M; Jurriaans S; Kootstra NA; Anderson PL; Reiss P; de Vries HJC; Prins JM; de Bree GJ;
Lancet HIV; 2017 Nov; 4(11):e522-e528. PubMed ID: 28919303
[TBL] [Abstract][Full Text] [Related]
9. Antiretroviral agents in pre-exposure prophylaxis: emerging and advanced trends in HIV prevention.
Yap PK; Loo Xin GL; Tan YY; Chellian J; Gupta G; Liew YK; Collet T; Dua K; Chellappan DK
J Pharm Pharmacol; 2019 Sep; 71(9):1339-1352. PubMed ID: 31144296
[TBL] [Abstract][Full Text] [Related]
10. Depot Medroxyprogesterone Acetate and the Vaginal Microbiome as Modifiers of Tenofovir Diphosphate and Lamivudine Triphosphate Concentrations in the Female Genital Tract of Ugandan Women: Implications for Tenofovir Disoproxil Fumarate/Lamivudine in Preexposure Prophylaxis.
Nicol MR; Eneh P; Nakalega R; Kaiser T; Kabwigu S; Isingel E; Beksinska M; Sykes C; Fowler MG; Brown TT; Staley C; Kiweewa Matovu F
Clin Infect Dis; 2020 Apr; 70(8):1717-1724. PubMed ID: 31131846
[TBL] [Abstract][Full Text] [Related]
11. Failure of pre-exposure prophylaxis with daily tenofovir/emtricitabine and the scenario of delayed HIV seroconversion.
Lee SS; Anderson PL; Kwan TH; Lui GCY; Chan DPC; Wong NS; Lee KCK; Lam TTN
Int J Infect Dis; 2020 May; 94():41-43. PubMed ID: 32173577
[TBL] [Abstract][Full Text] [Related]
12. Urine assay for tenofovir to monitor adherence in real time to tenofovir disoproxil fumarate/emtricitabine as pre-exposure prophylaxis.
Koenig HC; Mounzer K; Daughtridge GW; Sloan CE; Lalley-Chareczko L; Moorthy GS; Conyngham SC; Zuppa AF; Montaner LJ; Tebas P
HIV Med; 2017 Jul; 18(6):412-418. PubMed ID: 28444867
[TBL] [Abstract][Full Text] [Related]
13. InterPrEP: internet-based pre-exposure prophylaxis with generic tenofovir disoproxil fumarate/emtrictabine in London - analysis of pharmacokinetics, safety and outcomes.
Wang X; Nwokolo N; Korologou-Linden R; Hill A; Whitlock G; Day-Weber I; McClure MO; Boffito M
HIV Med; 2018 Jan; 19(1):1-6. PubMed ID: 28657199
[TBL] [Abstract][Full Text] [Related]
14. Expression, Activity, and Regulation of Phosphorylating Enzymes in Tissues and Cells Relevant to HIV-1 Sexual Transmission.
Hu M; Valicherla GR; Zhou T; Hillier SL; Rohan LC
AIDS Res Hum Retroviruses; 2022 Jan; 38(1):22-32. PubMed ID: 33567990
[TBL] [Abstract][Full Text] [Related]
15. Short Communication: Association of Vitamin D Insufficiency and Protective Tenofovir Diphosphate Concentrations with Bone Toxicity in Adolescent Boys and Young Men Using Tenofovir Disoproxil Fumarate/Emtricitabine for HIV Pre-Exposure Prophylaxis.
Havens PL; Tamhane A; Stephensen CB; Schuster GU; Gordon CM; Liu N; Wilson CM; Hosek SG; Anderson PL; Kapogiannis BG; Mulligan K
AIDS Res Hum Retroviruses; 2019 Feb; 35(2):123-128. PubMed ID: 30280906
[TBL] [Abstract][Full Text] [Related]
16. Safety of oral tenofovir disoproxil fumarate-based pre-exposure prophylaxis for HIV prevention.
Mugwanya KK; Baeten JM
Expert Opin Drug Saf; 2016; 15(2):265-73. PubMed ID: 26634852
[TBL] [Abstract][Full Text] [Related]
17. Pre-exposure prophylaxis to prevent HIV infection: current status, future opportunities and challenges.
Krakower DS; Mayer KH
Drugs; 2015 Feb; 75(3):243-51. PubMed ID: 25673022
[TBL] [Abstract][Full Text] [Related]
18. Penetration of tenofovir and emtricitabine in mucosal tissues: implications for prevention of HIV-1 transmission.
Patterson KB; Prince HA; Kraft E; Jenkins AJ; Shaheen NJ; Rooney JF; Cohen MS; Kashuba AD
Sci Transl Med; 2011 Dec; 3(112):112re4. PubMed ID: 22158861
[TBL] [Abstract][Full Text] [Related]
19. Low prevalence of transmitted K65R and other tenofovir resistance mutations across different HIV-1 subtypes: implications for pre-exposure prophylaxis.
Chan PA; Huang A; Kantor R
J Int AIDS Soc; 2012 Oct; 15(2):17701. PubMed ID: 23305651
[TBL] [Abstract][Full Text] [Related]
20. Maximizing the Benefits of HIV Preexposure Prophylaxis.
Buchbinder SP
Top Antivir Med; 2018 Apr; 25(4):138-142. PubMed ID: 29689539
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
